XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
3.91
+0.03 (0.77%)
Aug 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.70 - 3.97
52 week 3.42 - 9.57
Open 3.89
Vol / Avg. 1.49M/1.44M
Mkt cap 417.97M
P/E     -
Div/yield     -
EPS -1.13
Shares 106.90M
Beta 2.81
Inst. own 77%
Aug 14, 2014
XOMA Corp at Canaccord Genuity Growth Conference - 11:30AM EDT - Add to calendar
Aug 13, 2014
XOMA Corp at Wedbush Securities Life Sciences Conference - 8:35AM EDT - Add to calendar
Aug 7, 2014
Q2 2014 XOMA Corp Earnings Call - 4:30PM EDT - Add to calendar
Aug 7, 2014
Q2 2014 XOMA Corp Earnings Release - 4:00PM EDT - Add to calendar
Jul 8, 2014
XOMA Corp at Piper Jaffray Catalyst Symposium
Jun 30, 2014
XOMA Corp Communication Plan for EYEGUARD(TM)-B Clinical Program Conference Call - Webcast
Jun 3, 2014
XOMA at Jefferies Global Healthcare Conference
May 22, 2014
XOMA Annual Shareholder Meeting
May 14, 2014
XOMA at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Q1 2014 XOMA Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -137.45% -349.94%
Operating margin -688.39% -164.18%
EBITD margin - -155.08%
Return on average assets -15.51% -103.18%
Return on average equity - -1419.43%
Employees 172 -
CDP Score - -

Address

2910 SEVENTH ST
BERKELEY, CA 94710
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frederick Kurland Chief Financial Officer, Vice President - Finance, Secretary
Age: 63
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Tom Klein Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Kelvin M. Neu M.D. Director
Age: 41
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 87
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 79
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 61
Bio & Compensation  - Reuters